Merck & Co. MRK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $8.93B-51.1% | $18.26B-4.1% | $19.04B+16.0% | $16.42B-5.9% | $17.45B+1.9% | ||
| $810M-1.2% | $820M+2.2% | $802M+1.1% | $793M+1.7% | $780M+2.5% | ||
| -$1.8B-7.7% | -$1.67B-14.3% | -$1.46B+11.4% | -$1.65B-19.3% | -$1.38B-10.8% | ||
| —— | $1.09B+24.1% | $878.5M+31.7% | $667M+46.4% | $455.5M+86.7% | ||
| —— | $1.18B+7.9% | $1.09B+8.6% | $1.01B+9.4% | $921.25M+10.3% | ||
| —— | $110M-14.1% | $128M-12.3% | $146M-11.0% | $164M-9.9% | ||
| —— | -$1.84B+6.2% | -$1.96B+5.8% | -$2.08B+5.5% | -$2.21B+5.2% | ||
| —— | $195M+45.5% | $134M+83.6% | $73M+508% | $12M+124% | ||
| —— | $137M-61.8% | $358.5M-38.2% | $580M-27.6% | $801.5M-21.7% | ||
| $17.89B+8.6% | $16.47B-3.5% | $17.07B-7.9% | $18.53B-11.2% | $20.88B-2.7% | ||
| $3.78B-8.2% | $4.11B+2.4% | $4.02B+5.4% | $3.81B-0.7% | $3.84B+13.8% | ||
| $18.82B+87.4% | $10.04B+847% | -$1.34B-80.2% | -$746M0.0% | -$746M— | ||
| —— | —— | —— | $1.66B+51.2% | $1.1B+112% | ||
| -$22.46B-63.5% | -$13.74B-245% | -$3.98B+47.2% | -$7.55B+3.8% | -$7.85B-1.4% | ||
| $8.23B+0.7% | $8.18B+0.8% | $8.11B+1.0% | $8.03B+1.1% | $7.94B+1.3% | ||
| $4.79B-5.7% | $5.08B+17.7% | $4.32B+25.5% | $3.44B+46.6% | $2.35B+79.8% | ||
| $1.14B-54.3% | $2.5B-17.7% | $3.04B— | —— | —— | ||
| $230M+150% | $92M+61.4% | $57M+18.8% | $48M-56.0% | $109M-38.4% | ||
| —— | —— | —— | -$14.75B— | —— | ||
| $388M-31.1% | $563M+225% | $173M-62.1% | $457M+45,600% | $1M+100% | ||
| —— | —— | —— | —— | —— | ||
| -$473M+15.8% | -$562M— | —— | —— | —— | ||
| $3.13B+12.0% | $2.79B+11.9% | $2.5B-0.4% | $2.51B-0.5% | $2.52B+5.2% | ||
| $3.12B+2.6% | $3.05B+46.8% | $2.07B-1.0% | $2.1B0.0% | $2.1B-0.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | $110M-14.1% | $128M-12.3% | $146M-11.0% | $164M-9.9% | ||
| —— | —— | —— | —— | —— | ||
| -$473M+15.8% | -$562M— | —— | —— | —— | ||
| $8.54B— | $0-100% | $700M-75.0% | $2.8B0.0% | $2.8B-19.0% | ||
| $109M+73.0% | $63M+221% | -$52M— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | -$328M+7.3% | -$354M+4.8% | ||
| —— | —— | —— | —— | —— | ||
| $14.12B+14.2% | $12.36B-5.3% | $13.05B-11.4% | $14.72B-13.6% | $17.04B-5.8% | ||
| $14.12B+14.2% | $12.36B-5.3% | $13.05B-11.4% | $14.72B-13.6% | $17.04B-5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Merck & Co. generate?
- Merck & Co. (MRK) generated $17.9B in operating cash flow over the trailing twelve months.
- What is Merck & Co.'s free cash flow?
- After $3.8B of capital expenditures, Merck & Co.'s free cash flow was $14.1B over the trailing twelve months, down 17.2% year over year.
- Where does Merck & Co.'s cash flow data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
